LAW OFFICES
HYMAN, PHELPS & MCNAMARA, P.C.
700 THIRTEENTH STREET, N.W.
SUITE 1200
WASHINGTON, D. C. 20005-5929
(202) 737-5600
FACSIMILE
(202) 737-9329
www.hpm.com

ROBERT A. DORMER

Direct Dial (202) 737-4282
RDormer@hpm.com

December 16, 2014

BY FEDERAL EXPRESS

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane
Room 1061, HFA-305
Rockville, MD 02852

WITHDRAWAL OF CITIZEN PETITION
(DOCKET NUMBER FDA-2013-P-0283)

On March 8, 2013, the undersigned submitted a citizen petition under 21 C.F.R. § 10.30 to request that the Commissioner of Food and Drugs require certain labeling statements and risk mitigation activities in connection with CINRYZE and BERINERT, C1 Esterase Inhibitor (Human) products for the treatment of hereditary angioedema. As noted in a letter from the Division of Dockets Management (DDM) dated March 8, 2013, DDM received the petition on March 8, 2013, and filed the petition on March 8, 2013. DDM docketed the petition under number **FDA-2013-P-0283**.

The undersigned now withdraws this petition pursuant to 21 C.F.R. § 10.30(g).

Respectfully submitted,

Robert A Dorm

Robert A. Dormer

cc: Laura A. Rich
Director of Regulations and Policy Staff
Office of the Director, CBER